Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients.

Cressey TR, Nangola S, Tawon Y, Pattarawarapan M, Lallemant M, Tayapiwatana C.

Antimicrob Agents Chemother. 2007 Sep;51(9):3361-3. Epub 2007 Jul 2.

2.

Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection.

van Heeswijk RP, Hoetelmans RM, Meenhorst PL, Mulder JW, Beijnen JH.

J Chromatogr B Biomed Sci Appl. 1998 Aug 25;713(2):395-9.

PMID:
9746255
3.

Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique.

Lamorde M, Fillekes Q, Sigaloff K, Kityo C, Buzibye A, Kayiwa J, Merry C, Nakatudde-Katumba L, Burger D, de Wit TF.

BMC Infect Dis. 2014 Sep 1;14:473. doi: 10.1186/1471-2334-14-473.

4.

Detection of nevirapine in plasma using thin-layer chromatography.

Dubuisson JG, King JR, Stringer JS, Turner ML, Bennetto C, Acosta EP.

J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):155-7.

PMID:
14722448
5.

Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.

Chaix ML, Ekouevi DK, Peytavin G, Rouet F, Tonwe-Gold B, Viho I, Bequet L, Amani-Bosse C, Menan H, Leroy V, Rouzioux C, Dabis F.

Antimicrob Agents Chemother. 2007 Mar;51(3):896-901. Epub 2006 Dec 18.

6.

Simple and rapid determination of nevirapine in human serum by reversed-phase high-performance liquid chromatography.

Lopez RM, Pou L, Gomez MR, Ruiz I, Monterde J.

J Chromatogr B Biomed Sci Appl. 2001 Feb 25;751(2):371-6.

PMID:
11236094
7.

Sensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patients.

Azoulay S, Nevers MC, Créminon C, Heripret L, Durant J, Dellamonica P, Grassi J, Guedj R, Duval D.

Antimicrob Agents Chemother. 2004 Jan;48(1):104-9.

8.

Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir.

Donnerer J, Kronawetter M, Kapper A, Haas I, Kessler HH.

Pharmacology. 2003 Dec;69(4):197-204.

PMID:
14624060
9.

Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi.

Calcagno A, Motta I, Milia MG, Rostagno R, Simiele M, Libanore V, Fontana S, D'Avolio A, Ghisetti V, Di Perri G, Bonora S.

Br J Clin Pharmacol. 2015 May;79(5):801-8. doi: 10.1111/bcp.12544.

10.

[Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia].

Martorell M, López RM, Ribera E, Ruiz I, Tural C, Puig L, Monterde J.

Enferm Infecc Microbiol Clin. 2005 Jun-Jul;23(6):349-52. Spanish.

PMID:
15970167
11.

Simultaneous determination of zidovudine and nevirapine in human plasma by RP-LC.

Marchei E, Valvo L, Pacifici R, Pellegrini M, Tossini G, Zuccaro P.

J Pharm Biomed Anal. 2002 Aug 1;29(6):1081-8.

PMID:
12110393
13.

Determination of nevirapine in plasma by GC-MS.

Vogel M, Bertram N, Wasmuth JC, Emmelkamp J, Rockstroh JK, Reichel C.

J Chromatogr Sci. 2010 Feb;48(2):91-4.

PMID:
20109283
14.

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals.

Almond LM, Edirisinghe D, Dalton M, Bonington A, Back DJ, Khoo SH.

Clin Pharmacol Ther. 2005 Aug;78(2):132-42.

PMID:
16084848
15.

Bioequivalence study of two nevirapine tablet formulations in human-immunodeficiency-virus-infected patients.

Tarinas A, Tápanes RD, González D, Ferrer G, Abreu D, Pérez J.

Farm Hosp. 2007 May-Jun;31(3):165-8.

16.

Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection.

Rakhmanina NY, Capparelli EV, van den Anker JN, Williams K, Sever JL, Spiegel HM, Soldin SJ.

Ther Drug Monit. 2007 Feb;29(1):110-7.

PMID:
17304158
17.

Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.

Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Likanonsakul S, Ruxrungtham K.

Clin Infect Dis. 2006 Jul 15;43(2):253-5. Epub 2006 Jun 12.

PMID:
16779754
18.

Therapeutic drug monitoring of nevirapine in resource-limited settings.

L'homme RF, Muro EP, Droste JA, Wolters LR, van Ewijk-Beneken Kolmer NW, Schimana W, Burger DM.

Clin Infect Dis. 2008 Nov 15;47(10):1339-44. doi: 10.1086/592694.

PMID:
18922070
19.

Sex differences in nevirapine disposition in HIV-infected patients.

Regazzi M, Villani P, Seminari E, Ravasi G, Cusato M, Marubbi F, Meneghetti G, Maserati R.

AIDS. 2003 Nov 7;17(16):2399-400. No abstract available.

PMID:
14571195
20.

Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon.

Kouanfack C, Laurent C, Peytavin G, Ciaffi L, Ngolle M, Nkene YM, Essomba C, Calmy A, Mpoudi-Ngolé E, Delaporte E, Koulla-Shiro S; French National Agency for Research on AIDS 1274 Study Group..

J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):216-9. doi: 10.1097/QAI.0b013e3181743955.

PMID:
18520681

Supplemental Content

Support Center